Deferoxamine (DFO), an iron chelator, has demonstrated beneficial effects in clinical trials for AD patients and improves cognitive deficits induced by iron overload in APP/PS1 transgenic mice by inhibiting the processing of amyloid precursor protein (APP) [393,394,395]. Here, APP is linked to Alzheimer disease.